Norovirus is the causing agent of acute gastroenteritis disease globally. Efforts in developing therapeutics against virus infection mostly fail due to emergence of drug resistance that is a consequence of presence of high mutation rates in virus genome during virus' life cycle. In this study, we computationally analyzed the affinity of a drug target, wild type VP1 envelope protein and its three variants to a therapeutic antibody FAB5I2. We have found that mutations break important hydrogen bonds and cause high fluctuations in residues that form VP1–FAB5I2 complex interface. In addition to changes in dynamics, we also revealed that the affinity of FAB5I2 to VP1 protein drops significantly upon mutations in terms of relative binding free energy.
Get full access to this article
View all access options for this article.
References
1.
AbrahamM.J., MurtolaT., SchulzR., et al.2015. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 1–2, 19–25.
2.
AliabadiN., LopmanB.A., ParasharU.D., et al.2015. Progress toward norovirus vaccines: Considerations for further development and implementation in potential target populations. Expert. Rev. Vaccines. 14, 1241–1253.
3.
BakerN.A., SeptD., JosephS., et al.2001. Electrostatics of nanosystems: Application to microtubules and the ribosome. Proc. Natl. Acad. Sci. U. S. A. 98, 10037–10041.
4.
BelliotG., LopmanB.A., Ambert-BalayK., et al.2014. The burden of norovirus gastroenteritis: An important foodborne and healthcare-related infection. Clin. Microbiol. Infect. 20, 724–730.
5.
BernsteinD.I., AtmarR.L., LyonG.M., et al.2015. Norovirus vaccine against experimental human GII.4 virus illness: A challenge study in healthy adults. J. Infect. Dis. 211, 870–878.
6.
BullR.A., EdenJ.S., RawlinsonW.D., et al.2010. Rapid evolution of pandemic noroviruses of the GII.4 lineage. PLoS Pathog. 6, e1000831.
7.
CaddyS., BreimanA., le PenduJ., et al.2014. Genogroup IV and VI canine noroviruses interact with histo-blood group antigens. J. Virol. 88, 10377–10391.
8.
DardenT.A., YorkD., and PedersenL.1993. J. Chem. Phys. 98, 10089.
9.
DebbinkK., LindesmithL.C., DonaldsonE.F., et al.2013. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J. Infect. Dis. 208, 1877–1887.
10.
de GraafM., van BeekJ., and KoopmansM.P.2016. Human norovirus transmission and evolution in a changing world. Nat. Rev. Microbiol. 14, 421–433.
11.
DeLanoW.L.2002. The PyMOL Molecular Graphics System. Delano Scientific, San Carlos, CA.
12.
EmsleyP., and CowtanK.2004. Coot: Model-building tools for molecular graphics. Acta. Crystallogr. D. Biol. Crystallogr. 60(12 Part 1), 2126–2132.
13.
GaraicoecheaL., AguilarA., ParraG.I., et al.2015. Llama nanoantibodies with therapeutic potential against human norovirus diarrhea. PLoS One. 10, e0133665.
14.
Hoa TranT.N., TrainorE., NakagomiT., et al.2013. Molecular epidemiology of noroviruses associated with acute sporadic gastroenteritis in children: Global distribution of genogroups, genotypes and GII.4 variants. J. Clin. Virol. 56, 185–193.
15.
KambhampatiA., KoopmansM., and LopmanB.A.2015. Burden of norovirus in healthcare facilities and strategies for outbreak control. J. Hosp. Infect. 89, 296–301.
16.
KarstS.M., ZhuS., and GoodfellowI.G.2015. The molecular pathology of noroviruses. J. Pathol. 235, 206–216.
17.
KarstS.M., WobusC.E., GoodfellowI.G., et al.2014. Advances in norovirus biology. Cell. Host. Microbe. 15, 668–680.
18.
KocakA., ErolI., YildizM., et al.2016. Computational insights into the protonation states of catalytic dyad in BACE1-acyl guanidine based inhibitor complex. J. Mol. Graph. Model. 70, 226–235.
19.
KocakA., and YildizM.2017. Docking, molecular dynamics and free energy studies on aspartoacylase mutations involved in Canavan disease. J. Mol. Graph. Model. 74, 44–53.
20.
KotloffK.L., NataroJ.P., BlackwelderW.C., et al.2013. Burden and aetiology of diarrhoeal disease in infants and young children. Lancet. 382, 209–222.
21.
KubotaT., KumagaiA., ItoH., et al.2012. Structural basis for the recognition of Lewis antigens by genogroup I norovirus. J. Virol. 86, 11138–11150.
22.
KumariR., KumarR., and LynnA.2014. g_mmpbsa—A GROMACS tool for high-throughput MM-PBSA calculations. J. Chem. Inform. Model. 54, 1951–1962.
Lindorff-LarsenK., PianaS., PalmoK., et al.2010. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins. 78, 1950–1958.
25.
LochridgeV.P., JutilaK.L., GraffJ.W., et al.2005. Epitopes in the P2 domain of norovirus VP1 recognized by monoclonal antibodies that block cell interactions. J. Gen. Virol. 86(Pt 10), 2799–2806.
26.
OlssonM.H.M., SøndergaardC.R., RostkowskiM., et al.2011. PROPKA3: Consistent treatment of internal and surface residues in empirical pKa predictions. J. Chem. Theory Comput. 7, 525–537.
27.
PatelM.M., HallA.J., VinjeJ., et al.2009. Noroviruses: A comprehensive review. J. Clin. Virol. 44, 1–8.
28.
RobilottiE., DeresinskiS., and PinskyB.A.2015. Norovirus. Clin. Microbiol. Rev. 28, 134–164.
29.
Rocha-PereiraJ., NeytsJ., and JochmansD.2014. Norovirus: Targets and tools in antiviral drug discovery. Biochem. Pharmacol. 91, 1–11.
30.
Ruvoen-ClouetN., BelliotG., and Le PenduJ.2013. Noroviruses and histo-blood groups: The impact of common host genetic polymorphisms on virus transmission and evolution. Rev. Med. Virol. 23, 355–366.
31.
SapparapuG., CzakoR., AlvaradoG., et al.2016. Frequent use of the IgA isotype in human B cells encoding potent norovirus-specific monoclonal antibodies that block HBGA binding. PLoS Pathog. 12, e1005719.
32.
SchrödingerL.2015. Maestro. Schrödinger Release 2015-2. Schrödinger, LLC, New York, NY.
33.
ShankerS., CzakoR., SankaranB., et al.2014. Structural analysis of determinants of histo-blood group antigen binding specificity in genogroup I noroviruses. J. Virol. 88, 6168–6180.
34.
ShankerS., CzakoR., SapparapuG., et al.2016. Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody. Proc. Natl. Acad. Sci. U. S. A. 113, E5830–E5837.
35.
TamminenK., MalmM., VesikariT., et al.2016. Mucosal antibodies induced by intranasal but not intramuscular immunization block norovirus GII.4 virus-like particle receptor binding. Viral. Immunol. 29, 315–319.
36.
TanM., and JiangX.2014. Vaccine against norovirus. Hum. Vaccin. Immunother. 10, 1449–1456.
37.
ToukanK., and RahmanA.1985. Molecular-dynamics study of atomic motions in water. Phys. Rev. B. 31, 2643–2648.
38.
WhiteP.A.2014. Evolution of norovirus. Clin. Microbiol. Infect. 20, 741–745.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
